Memantine + Placebo
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psychosis
Conditions
Psychosis, Negative Symptoms With Primary Psychotic Disorder
Trial Timeline
May 26, 2021 → Dec 31, 2026
NCT ID
NCT04789915About Memantine + Placebo
Memantine + Placebo is a phase 1 stage product being developed by Lundbeck for Psychosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04789915. Target conditions include Psychosis, Negative Symptoms With Primary Psychotic Disorder.
What happened to similar drugs?
3 of 17 similar drugs in Psychosis were approved
Approved (3) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
6
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04789915 | Phase 1 | Recruiting |
| NCT00638833 | Phase 2 | Terminated |
| NCT00855686 | Approved | Completed |
| NCT01074619 | Phase 3 | Completed |
| NCT00862940 | Approved | Completed |
| NCT00857649 | Phase 3 | Terminated |
Competing Products
20 competing products in Psychosis